Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma


Original post, click here
This study is currently recruiting participants.

See

Verified June 2017 by FanQingxia, The First Affiliated Hospital of Zhengzhou University

Sponsor:

Information provided by (Responsible Party):

FanQingxia, The First Affiliated Hospital of Zhengzhou University

ClinicalTrials.gov Identifier:

NCT03193424

First received: June 17, 2017

Last updated: June 19, 2017

Last verified: June 2017

Esophageal cancer is a common malignant tumor in china, occupies the second place of malignant tumor morbidity and mortality, the overall 5-year survival rate less than 20%.

Advanced Esophageal Squamous Carcinoma Drug: Apatinib Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Double Group Assignment,apatinib plus docetaxel comparison to docetaxel.

Masking: Investigator
Primary Purpose: Treatment

Official Title: A Prospective, Open-label, Randomized Controlled Clinical Study of Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment: 120
Actual Study Start Date: October 2016
Estimated Study Completion Date: December 30, 2019
Estimated Primary Completion Date: December 30, 2018 (Final data collection date for primary outcome measure)
Experimental: Apatinib Drug: Apatinib

Subjects were randomly divided into two groups,A group:apatinib 500mg/d,po,qd, Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) . B group:Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) .

Other Name: Docetaxel

Active Comparator: docetaxel Drug: Apatinib

Subjects were randomly divided into two groups,A group:apatinib 500mg/d,po,qd, Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) . B group:Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) .

Other Name: Docetaxel

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age: 18 years old to 75 years old, male and female is ok.
  • Esophageal squamous cell carcinoma diagnosed by histopathology and immunohistochemistry. At least one treated measurable lesion (spiral CT scan length ≥10mm, in line with RESCIST version 1.1 standard requirements);
  • Patients with advanced esophageal cancer treated by radiotherapy and treatment;
  • ECOG PS Rating: 0-1 points;
  • Expected survival ≥12 weeks;
  • Without molecular targeted drug therapy.
  • The main organ function is normal, that is to meet the following criteria:

Blood test:a.HB≥90 g/L;b.ANC≥1.5×109/L;c.PLT ≥80×109/L; Biochemical tests:a.ALB≥30g / L;b. ALT和AST<2ULN;ALT and AST <2ULN;c.TBIL≤1.5ULN;Plasma Cr ≤ 1.5ULN;

  • Subjects volunteered to join the study, signed informed consent, compliance, with follow-up.
  • Researchers believe that patients can benefit.

Exclusion Criteria:

  • Patients who have been confirmed to be allergic to apatinib and / or its excipients;
  • Patients with uncontrollable hypertension (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg, despite optimal drug therapy), with grade Ⅱ myocardial ischemia or myocardial infarction, poor control of arrhythmias (including QTc interval male ≥ 450 ms, female ≥470 ms).According to NYHA standard, grade Ⅲ ~ Ⅳ heart failure, or cardiac color Doppler ultrasound examination showed left ventricular ejection fraction (LVEF) <50%.
  • Patients with a clear tendency to gastrointestinal bleeding, including the following: localized ulcer lesions, and fecal occult blood (++) can not be grouped; 2 months with black, hematemesis history;
  • Coagulation dysfunction (INR> 1.5, APTT> 1.5 ULN), with bleeding tendency;
  • (Eg, no swallowing, nausea, vomiting, chronic diarrhea and intestinal obstruction, etc.) that affect the absorption of oral medications;
  • The patients with active brain metastases(without medical control) , cancer meningitis, spinal cord compression, or screening of imaging CT or MRI examination found that the brain or pia mater disease (21 days before the completion of treatment and symptoms of stable brain Metastasis patients can be grouped, but the need for transcranial MRI, CT or intravenous angiography, confirmed as no cerebral hemorrhage symptoms)
  • Pregnant or lactating women
  • Subject with other malignancies within 5 years(except the skin basal cell carcinoma and cervical in situ cancer that have already cured )
  • Subject with a history of psychiatric abuse and who can not be abused or have mental disorders;
  • Subject who participated in other drug clinical trials within 4 weeks.
  • Subject who have received VEGFR inhibitors such as sorafenib, sunitinib;
  • According to the investigator’s judgment, there are serious illnesses that compromise the patient’s safety or affect the patient’s completion of the study;
  • Researchers think it is not suitable for inclusion.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03193424

The First Affiliated Hospital of Zhengzhou University

Responsible Party: FanQingxia, Director, The First Affiliated Hospital of Zhengzhou University
ClinicalTrials.gov Identifier: NCT03193424     History of Changes
Other Study ID Numbers: AHEAD-HNP001
Study First Received: June 17, 2017
Last Updated: June 19, 2017
Individual Participant Data  
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Carcinoma
Carcinoma, Squamous Cell
Esophageal Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Docetaxel
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 20, 2017